心不全の疑いのあるコミュニティベースの患者の病気修正治療の早期開始の利点
Kieran F Docherty1, Benjamin Heywood2, Antoni Bayes-Genis3
1BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK.
European heart journal
|August 29, 2025
まとめ
疑われる心不全 (HF) と高濃度のNT- プロBNPを有する患者に,ナトリウム・グルコース共輸送体2阻害剤 (SGLT2i) とミネラルコルチコイド受容体抗体 (MRA) を早期に投与すると,入院および死亡率を減らすことができる. この戦略はHFの早期リスク管理に 重要な公衆衛生上の利点をもたらします
科学分野:
- 心臓病科
- 薬理学について
- 公衆衛生
背景:
- 心不全の疑いのある患者のN- 末端プロB型ナトリウレチンペプチド (NT- proBNP) 濃度の上昇は,リスクの増加を示しています.
- HF治療の早期開始は,有害な結果を防ぐことができます.
- ナトリウム・グルコース・コトランスポーター2阻害剤 (SGLT2i) とミネラルコルチコイド受容体抗体 (MRA) は,HFの効果的な治療法である.
研究 の 目的:
- HFの疑いのある患者およびこれらの薬剤の非HF用性における早期のSGLT2iおよび/またはMRA開始の利点を推定する.
- HFの入院や死亡などの早期の有害な結果への影響を評価する.
主な方法:
- 2015年から2023年までの英国の初等・二次医療データ (CPRD) を用いた12ヶ月のコホート研究.
- NT- proBNP ≥400 pg/ mL,以前のHF歴なし,SGLT2i/ MRAの処方箋のない患者を含む.
- NT-proBNP測定でSGLT2i/MRA開始のためのランダム化試験のメタ解析から治療効果をモデル化した.
主要な成果:
- NT- proBNP ≥400 pg/ mLの患者74, 945人のうち,32%が12ヶ月以内にHFの診断を受けた.
- SGLT2iとMRAの両方を早期に開始すると,治療を受けた1000人に84人のHF入院または死亡を防ぐことが推定されました.
- これは治療に必要な数値12 (95%CI11-14) に相当する.
結論:
- 早期のSGLT2iとMRAの開始は,HFが疑われ,NT-proBNPが上昇した,既にある症状を持つ患者で,早期の有害事象を減らすことができます.
- この臨床戦略は,エコーカルディオグラフィーを待つ間,公衆衛生に重大な利益をもたらす可能性があることを示しています.
- 初期段階の心不全リスクを管理するための シンプルで効果的なアプローチを 支持しています
関連する概念動画
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:29Cardiomyopathy V: Interprofessional Care
32
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
32
01:21Rheumatic Heart Disease III: Medical Management
31
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
31
01:30Heart Failure IV: Classification and Diagnostic Evaluation
32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32